Sildenafil and tadalafil (Viagra and Cialis) work on blood flow. They are the correct drugs for erectile dysfunction rooted in vascular problems. PT-141 works on desire itself. It targets the brain's melanocortin system, the neurological circuitry that drives motivation, reward, and arousal, creating the foundation for sexual response before the physical response happens.
For men whose erectile dysfunction or low libido has a central or psychological component, PT-141 addresses the root mechanism that PDE5 inhibitors cannot touch. It is FDA-approved for hypoactive sexual desire disorder (HSDD) in women; off-label use in men for low libido and ED with a psychological or central component is supported by emerging evidence.
Includes ongoing provider care & support
Compounded medication · Platform access
PT-141 works through a mechanism distinct from all other ED and libido therapies. These are the facts about how it works.
PT-141 (bremelanotide) is FDA-approved for women; use in men is off-label. Individual response varies. This is a compounded preparation. Results are not guaranteed.
PT-141 is a potent agonist at melanocortin 3 and 4 receptors (MC3R and MC4R) located in the hypothalamus. Activation increases dopaminergic signaling in reward and arousal pathways, creating the neurological foundation for sexual response.
Unlike sildenafil and tadalafil, which work on peripheral blood vessels, PT-141 acts directly on the central nervous system. It is effective even in low-arousal states where vascular dysfunction is not the limiting factor; it addresses the desire component that PDE5 inhibitors cannot reach.
PT-141 can be safely combined with sildenafil or tadalafil under provider supervision. The combination addresses both components of sexual dysfunction, the desire/arousal component (PT-141) and the mechanical/vascular component (PDE5 inhibitor), simultaneously.
PT-141 is a prescription medication. Your Obsidian Genetics provider will review your full health history before prescribing.
PT-141 can cause a temporary rise in blood pressure. Do not use if you are on antihypertensive medications without explicit provider clearance. Monitor blood pressure closely if you have hypertension. Avoid combined use with nitrate medications (nitroglycerin) and use extreme caution if combining with PDE5 inhibitors in men with cardiovascular disease.
Important: PT-141 (bremelanotide) as formulated here is a compounded preparation. It is not an FDA-approved drug product. Compounded medications are not reviewed by the FDA for safety, efficacy, or manufacturing standards. This product is prescribed by a licensed provider and prepared by a licensed compounding pharmacy for individual patient use. Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women only; use in men is off-label. PT-141 enhances desire and arousal through melanocortin pathway activation. It does not address testosterone deficiency directly. If your low libido or ED is rooted in hypogonadism (low testosterone), testosterone therapy or monitoring should be addressed first. PT-141 can complement testosterone therapy but does not replace it. This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any new treatment. All Obsidian Genetics prescriptions are issued following a clinical review by a licensed provider. PT-141 is prescribed by licensed Obsidian Genetics providers following a clinical intake review. Your provider assesses your sexual and medical history, cardiovascular status, current medications, and goals before prescribing. PT-141 is not appropriate for everyone; your provider determines whether it is right for you.